Publications

• Combining DNA methylation features and clinical characteristics predicts ketamine treatment response for PTSD.Valizadeh A, Roache JD, Zhang X, Hu Y, Gueorguieva R, Averill LA, Ranganathan M, Wang Z, Williamson DE, Shiroma PR, Girgenti MJ, Petrakis IL, López-Roca AL, Young-McCaughan S, Keane TM, Peterson AL, Abdallah CG, Krystal JH, Xu K. iScience. 2026 Jan 16; 2025 Dec 17. PMID: 41561376.
• Sponsorship and Career Advancement for Asian Medical Faculty.Sebastian D, Gonzalez Herrera K, Ranganathan M, Landeros-Weisenberger A, Latimore D. JAMA Netw Open. 2026 Jan 2; 2026 Jan 2. PMID: 41511770.
• A translational neuroscience & computational evaluation of a D1R partial agonist for schizophrenia (TRANSCENDS): Rationale and study design of a brain-based clinical trial.Fonteneau C, Tamayo Z, Price A, Pan L, Afriyie-Agyemang Y, Agrawal S, Butler A, Cail C, Calkins M, Chakilam AR, Forselius-Bielen K, Fram G, Frazier A, Gil R, Govil P, Gray DL, Grinband J, Gur RC, Haubold NK, Heffernan Z, Heneks M, Kegeles L, Kohler C, Lin C, Lu J, Mayer M, Pham P, Perlman G, Rahmati M, Ranganathan M, Santamauro NP, Schutte CW, Selloni A, Van Snellenberg J, Surti T, Wolf DH, Zharyy C, Abi-Dargham A, Gur RE, Lieberman JA, Kantrowitz JT, Anticevic A, Cho YT, Krystal JH. J Psychiatr Res. 2025 Dec 16; 2025 Dec 16. PMID: 41519104.
• Artificial Intelligence in Depression-Medication Enhancement (AID-ME): A Cluster Randomized Trial of a Deep-Learning-Enabled Clinical Decision Support System for Personalized Depression Treatment Selection and Management.Benrimoh D, Whitmore K, Richard M, Golden G, Perlman K, Jalali S, Friesen T, Barkat Y, Mehltretter J, Fratila R, Armstrong C, Israel S, Popescu C, Karp JF, Parikh SV, Golchi S, Moodie EEM, Shen J, Gifuni AJ, Ferrari M, Sapra M, Kloiber S, Pinard GF, Dunlop BW, Looper K, Ranganathan M, Enault M, Beaulieu S, Rej S, Hersson-Edery F, Steiner W, Anacleto A, Qassim S, McGuire-Snieckus R, Margolese HC. J Clin Psychiatry. 2025 Aug 27; 2025 Aug 27. PMID: 40875536.
• Cannabinoid Receptor Type 1 Availability in Individuals with a History of Childhood Trauma: A Positron Emission Tomography Study.Bassir Nia A, Aghaei AM, Pittman B, Korem N, D'Souza D, Potenza M, Hillmer A, Ranganathan M, Harpaz-Rotem I. Res Sq. 2025 May 30; 2025 May 30. PMID: 40502783.
• The Potential Use of Cannabidiol in the Treatment of Opioid Use Disorder: A Systematic Review.Shafie M, Ing K, Rostam-Abadi Y, Weleff J, Griffin M, Ranganathan M, Mohammad Aghaei A, Pratt N, Funaro MC, Bassir Nia A. Addict Biol. 2025 May. PMID: 40415392.
• A Translational Neuroscience & Computational Evaluation of a D1R Partial Agonist for Schizophrenia (TRANSCENDS): Rationale and Study Design of a Brain-Based Clinical Trial.Fonteneau C, Tamayo Z, Price A, Pan L, Afriyie-Agyemang Y, Agrawal S, Butler A, Cail C, Calkins M, Chakilam S, Forselius-Bielen K, Fram G, Frazier A, Gil R, Govil P, Gray DL, Grinband J, Gur RC, Haubold NK, Heffernan Z, Kegeles L, Kohler C, Lin C, Lu J, Mayer M, Pham P, Perlman G, Rahmati M, Ranganathan M, Santamauro NP, Schutte CT, Selloni A, Van Snellenberg J, Surti T, Wolf DH, Zharyy C, Abi-Dargham A, Gur RE, Lieberman JA, Kantrowitz JT, Anticevic A, Cho YT, Krystal JH. medRxiv. 2025 Apr 20; 2025 Apr 20. PMID: 40321245.
• Sex differences in the acute effects of oral THC: a randomized, placebo-controlled, crossover human laboratory study.Mohammad Aghaei A, Urban Spillane L, Pittman B, Flynn LT, De Aquino JP, Bassir Nia A, Ranganathan M. Psychopharmacology (Berl). 2024 Oct; 2024 Jun 4. PMID: 38832949.
• Sex Differences in the Acute Effects of Oral THC: A Randomized, Placebo-Controlled, Crossover Human Laboratory Study.Aghaei AM, Spillane LU, Pittman B, Flynn LT, De Aquino JP, Nia AB, Ranganathan M. medRxiv. 2024 Mar 12; 2024 Mar 12. PMID: 38077095.
• Clinical Outcomes of Intravenous Ketamine Treatment for Depression in the VA Health System.Pfeiffer PN, Geller J, Ganoczy D, Jagusch J, Carty J, Festin FED, Gilmer WS, Martis B, Ranganathan M, Wiechers IR, Hosanagar A. J Clin Psychiatry. 2024 Jan 8; 2024 Jan 8. PMID: 38206011.
• Delta-9-Tetrahydrocannabinol, Cannabidiol, and Acute Psychotomimetic States: A Balancing Act of the Principal Phyto-Cannabinoids on Human Brain and Behavior.Ganesh S, Cortes-Briones J, Schnakenberg Martin AM, Skosnik PD, D'Souza DC, Ranganathan M. Cannabis Cannabinoid Res. 2023 Oct; 2022 Mar 18. PMID: 35319274.
• Delta-9-tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within-subject, randomized, placebo-controlled laboratory study.De Aquino JP, Meyerovich J, Xie CZ, Ranganathan M, Compton P, Pittman B, Rogan M, Sofuoglu M. Addict Biol. 2023 Sep. PMID: 37644897.
• Peripheral signature of altered synaptic integrity in young onset cannabis use disorder: A proteomic study of circulating extracellular vesicles.Ganesh S, Lam TT, Garcia-Milian R, Cyril D'Souza D, Nairn AC, Elgert K, Eitan E, Ranganathan M. World J Biol Psychiatry. 2023 Sep-Oct; 2023 Apr 13. PMID: 36994633.
• Illness Phase as a Key Assessment and Intervention Window for Psychosis.Kohler CG, Wolf DH, Abi-Dargham A, Anticevic A, Cho YT, Fonteneau C, Gil R, Girgis RR, Gray DL, Grinband J, Javitch JA, Kantrowitz JT, Krystal JH, Lieberman JA, Murray JD, Ranganathan M, Santamauro N, Van Snellenberg JX, Tamayo Z, Gur RC, Gur RE, Calkins ME. Biol Psychiatry Glob Open Sci. 2023 Jul; 2022 Jun 18. PMID: 37519466.
• Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia.Surti TS, Ranganathan M, Johannesen JK, Gueorguieva R, Deaso E, Kenney JG, Krystal JH, D'Souza DC. Schizophr Res. 2023 Jun; 2023 May 2. PMID: 37141764.
• Preliminary study of the interactive effects of THC and ethanol on self-reported ability and simulated driving, subjective effects, and cardiovascular responses.Schnakenberg Martin AM, Flynn LT, Sefik E, Luddy C, Cortes-Briones J, Skosnik PD, Pittman B, Ranganathan M, D'Souza DC. Psychopharmacology (Berl). 2023 Jun; 2023 Apr 12. PMID: 37045988.
• Age, gender and body-mass-index relationships with in vivo CB(1) receptor availability in healthy humans measured with [(11)C]OMAR PET.Radhakrishnan R, Worhunsky PD, Zheng MQ, Najafzadeh S, Gallezot JD, Planeta B, Henry S, Nabulsi N, Ranganathan M, Skosnik PD, Pittman B, Cyril D'Souza D, Carson RE, Huang Y, Potenza MN, Matuskey D. Neuroimage. 2022 Dec 1; 2022 Oct 13. PMID: 36243269.
• Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis.D'Souza DC, DiForti M, Ganesh S, George TP, Hall W, Hjorthøj C, Howes O, Keshavan M, Murray RM, Nguyen TB, Pearlson GD, Ranganathan M, Selloni A, Solowij N, Spinazzola E. World J Biol Psychiatry. 2022 Dec; 2022 Mar 22. PMID: 35315315.
• Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder.D'Souza DC, Syed SA, Flynn LT, Safi-Aghdam H, Cozzi NV, Ranganathan M. Neuropsychopharmacology. 2022 Sep; 2022 Jun 3. PMID: 35660802.
• Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial.Oslin DW, Lynch KG, Shih MC, Ingram EP, Wray LO, Chapman SR, Kranzler HR, Gelernter J, Pyne JM, Stone A, DuVall SL, Lehmann LS, Thase ME, Aslam M, Batki SL, Bjork JM, Blow FC, Brenner LA, Chen P, Desai S, Dieperink EW, Fears SC, Fuller MA, Goodman CS, Graham DP, Haas GL, Hamner MB, Helstrom AW, Hurley RA, Icardi MS, Jurjus GJ, Kilbourne AM, Kreyenbuhl J, Lache DJ, Lieske SP, Lynch JA, Meyer LJ, Montalvo C, Muralidhar S, Ostacher MJ, Paschall GY, Pfeiffer PN, Prieto S, Przygodzki RM, Ranganathan M, Rodriguez-Suarez MM, Roggenkamp H, Schichman SA, Schneeweis JS, Simonetti JA, Steinhauer SR, Suppes T, Umbert MA, Vassy JL, Voora D, Wiechers IR, Wood AE. JAMA. 2022 Jul 12. PMID: 35819423.
• Correction to: Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial.Abdallah CG, Roache JD, Gueorguieva R, Averill LA, Young-McCaughan S, Shiroma PR, Purohit P, Brundige A, Murff W, Ahn KH, Sherif MA, Baltutis EJ, Ranganathan M, D'Souza D, Martini B, Southwick SM, Petrakis IL, Burson RR, Guthmiller KB, López-Roca AL, Lautenschlager KA, McCallin JP 3rd, Hoch MB, Timchenko A, Souza SE, Bryant CE, Mintz J, Litz BT, Williamson DE, Keane TM, Peterson AL, Krystal JH. Neuropsychopharmacology. 2022 Jul. PMID: 35545665.
• Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial.Abdallah CG, Roache JD, Gueorguieva R, Averill LA, Young-McCaughan S, Shiroma PR, Purohit P, Brundige A, Murff W, Ahn KH, Sherif MA, Baltutis EJ, Ranganathan M, D'Souza D, Martini B, Southwick SM, Petrakis IL, Burson RR, Guthmiller KB, López-Roca AL, Lautenschlager KA, McCallin JP 3rd, Hoch MB, Timchenko A, Souza SE, Bryant CE, Mintz J, Litz BT, Williamson DE, Keane TM, Peterson AL, Krystal JH. Neuropsychopharmacology. 2022 Jul; 2022 Jan 19. PMID: 35046508.
• Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC).Bassir Nia A, Orejarena MJ, Flynn L, Luddy C, D'Souza DC, Skosnik PD, Pittman B, Ranganathan M. Psychopharmacology (Berl). 2022 May; 2022 Apr 19. PMID: 35438304.
• mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression.Averill LA, Averill CL, Gueorguieva R, Fouda S, Sherif M, Ahn KH, Ranganathan M, D'Souza DC, Southwick SM, Sanacora G, Duman RS, Krystal JH, Abdallah CG. J Affect Disord. 2022 Apr 15; 2022 Jan 29. PMID: 35101523.
• Multimodal Correlates of Cannabis Use among U.S. Veterans with Bipolar Disorder: An Integrated Study of Clinical, Cognitive, and Functional Outcomes.Selloni A, Bhatia G, Ranganathan M, De Aquino JP. J Dual Diagn. 2022 Apr-Jun; 2022 Apr 17. PMID: 35430960.
• Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia.Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, Fonteneau C, Gil R, Girgis R, Gur RE, Gur RC, Grinband J, Kantrowitz J, Kohler C, Krystal J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Wolf D, Gray D, Lieberman J. Schizophr Bull. 2022 Jan 21. PMID: 34423843.
• Analysis of circulating exosomes reveals a peripheral signature of astrocytic pathology in schizophrenia.Ranganathan M, Rahman M, Ganesh S, D'Souza DC, Skosnik PD, Radhakrishnan R, Pathania S, Mohanakumar T. World J Biol Psychiatry. 2022 Jan; 2021 Apr 28. PMID: 33821753.
• In vivo evidence of lower synaptic vesicle density in schizophrenia.Radhakrishnan R, Skosnik PD, Ranganathan M, Naganawa M, Toyonaga T, Finnema S, Hillmer AT, Esterlis I, Huang Y, Nabulsi N, Carson RE, D'Souza DC. Mol Psychiatry. 2021 Dec; 2021 Jun 16. PMID: 34135473.
• Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder.D'Souza DC, Radhakrishnan R, Naganawa M, Ganesh S, Nabulsi N, Najafzadeh S, Ropchan J, Ranganathan M, Cortes-Briones J, Huang Y, Carson RE, Skosnik P. Mol Psychiatry. 2021 Jul; 2020 Sep 24. PMID: 32973170.
• Exocannabinoids, Endocannabinoids, and Psychosis.Radhakrishnan R, Ranganathan M, Skosnik PD, D'Souza DC. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021 Jun. PMID: 34099185.
• A robust and reproducible connectome fingerprint of ketamine is highly associated with the connectomic signature of antidepressants.Abdallah CG, Ahn KH, Averill LA, Nemati S, Averill CL, Fouda S, Ranganathan M, Morgan PT, D'Souza DC, Mathalon DH, Krystal JH, Driesen NR. Neuropsychopharmacology. 2021 Jan; 2020 Sep 23. PMID: 32967000.
• Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies.Ganesh S, Cortes-Briones J, Ranganathan M, Radhakrishnan R, Skosnik PD, D'Souza DC. Int J Neuropsychopharmacol. 2020 Dec 3. PMID: 32385508.
• Alterations in the Endocannabinoid System in Schizophrenia.Ranganathan M, D'Souza DC. Biol Psychiatry. 2020 Nov 1. PMID: 33032694.
• In an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers.Schindler EAD, Schnakenberg Martin AM, Sewell RA, Ranganathan M, DeForest A, Pittman BP, Perrino A Jr, D'Souza DC. Psychopharmacology (Berl). 2020 Oct; 2020 Jul 6. PMID: 32632491.
• Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia: A Systematic Review and Meta-analysis.Beck K, Hindley G, Borgan F, Ginestet C, McCutcheon R, Brugger S, Driesen N, Ranganathan M, D'Souza DC, Taylor M, Krystal JH, Howes OD. JAMA Netw Open. 2020 May 1; 2020 May 1. PMID: 32437573.
• Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin.Abdallah CG, Averill LA, Gueorguieva R, Goktas S, Purohit P, Ranganathan M, Sherif M, Ahn KH, D'Souza DC, Formica R, Southwick SM, Duman RS, Sanacora G, Krystal JH. Neuropsychopharmacology. 2020 May; 2020 Feb 24. PMID: 32092760.
• Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans.Hu Y, Ranganathan M, Shu C, Liang X, Ganesh S, Osafo-Addo A, Yan C, Zhang X, Aouizerat BE, Krystal JH, D'Souza DC, Xu K. Sci Rep. 2020 Feb 26; 2020 Feb 26. PMID: 32103029.
• Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans.Ranganathan M, De Aquino JP, Cortes-Briones JA, Radhakrishnan R, Pittman B, Bhakta S, D'Souza DC. Psychopharmacology (Berl). 2019 Nov; 2019 Jun 11. PMID: 31187152.
• Effects of haloperidol on the delta-9-tetrahydrocannabinol response in humans: a responder analysis.Gupta S, De Aquino JP, D'Souza DC, Ranganathan M. Psychopharmacology (Berl). 2019 Sep; 2019 Mar 27. PMID: 30919005.
• Medical Marijuana: What Physicians Need to Know.Radhakrishnan R, Ranganathan M, D'Souza DC. J Clin Psychiatry. 2019 May 7; 2019 May 7. PMID: 31087827.
• Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial.D'Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, Bielen K, Surti T, Radhakrishnan R, Gupta A, Gupta S, Cahill J, Sherif MA, Makriyannis A, Morgan PT, Ranganathan M, Skosnik PD. Lancet Psychiatry. 2019 Jan; 2018 Dec 6. PMID: 30528676.
• Cannabis Use: Neurobiological, Behavioral, and Sex/Gender Considerations.Nia AB, Mann C, Kaur H, Ranganathan M. Curr Behav Neurosci Rep. 2018 Dec; 2018 Nov 10. PMID: 31548918.
• The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol (Δ(9)-THC) in humans.Boggs DL, Cortes-Briones JA, Surti T, Luddy C, Ranganathan M, Cahill JD, Sewell AR, D'Souza DC, Skosnik PD. J Psychopharmacol. 2018 Dec; 2018 Sep 26. PMID: 30255720.
• Cannabinoid-glutamate interactions and neural oscillations: implications for psychosis.Sherif MA, Cortes-Briones JA, Ranganathan M, Skosnik PD. Eur J Neurosci. 2018 Oct; 2018 Jan 11. PMID: 29247465.
• Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects.D'Souza DC, Carson RE, Driesen N, Johannesen J, Ranganathan M, Krystal JH. Biol Psychiatry. 2018 Sep 15; 2018 Jan 31. PMID: 29499855.
• Acceptability of Mobile Phone-Based Nurse-Delivered Counseling Intervention to Improve HIV Treatment Adherence and Self-Care Behaviors Among HIV-Positive Women in India.Duggal M, Chakrapani V, Liberti L, Satyanarayna V, Varghese M, Singh P, Ranganathan M, Chandra P, Reynolds NR. AIDS Patient Care STDS. 2018 Sep. PMID: 30179531.
• The Psychiatric Consequences of Cannabinoids.De Aquino JP, Sherif M, Radhakrishnan R, Cahill JD, Ranganathan M, D'Souza DC. Clin Ther. 2018 Sep; 2018 Apr 17. PMID: 29678279.
• The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, Schnakenberg Martin AM, Thurnauer H, Davies A, D'Souza DC, Ranganathan M. Psychopharmacology (Berl). 2018 Jul; 2018 Apr 5. PMID: 29619533.
• Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humans.Skosnik PD, Hajós M, Cortes-Briones JA, Edwards CR, Pittman BP, Hoffmann WE, Sewell AR, D'Souza DC, Ranganathan M. Neuropharmacology. 2018 Jun; 2018 Mar 28. PMID: 29604295.
• Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the "self-medication" hypothesis in schizophrenia.Boggs DL, Surti TS, Esterlis I, Pittman B, Cosgrove K, Sewell RA, Ranganathan M, D'Souza DC. Schizophr Res. 2018 Apr; 2017 Apr 6. PMID: 28392208.
• Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ(9)-Tetrahydrocannabinol.Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M. Neuropsychopharmacology. 2018 Jan; 2017 Sep 6. PMID: 28875990.
• Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophrenia.Hamilton HK, D'Souza DC, Ford JM, Roach BJ, Kort NS, Ahn KH, Bhakta S, Ranganathan M, Mathalon DH. Schizophr Res. 2018 Jan; 2017 Jul 12. PMID: 28711472.
• Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information.Ranganathan M, Radhakrishnan R, Addy PH, Schnakenberg-Martin AM, Williams AH, Carbuto M, Elander J, Pittman B, Andrew Sewell R, Skosnik PD, D'Souza DC. Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 3; 2017 Jun 20. PMID: 28642081.
• Sublingual atropine in the treatment of clozapine-induced sialorrhea.Matos Santana TE, Capurso NA, Ranganathan M, Yoon G. Schizophr Res. 2017 Apr; 2016 Nov 2. PMID: 27816262.
• The role of psychedelics in palliative care reconsidered: A case for psilocybin.Kelmendi B, Corlett P, Ranganathan M, D'Souza C, Krystal JH. J Psychopharmacol. 2016 Dec. PMID: 27909173.
• Delta-9-tetrahydrocannabinol and cannabidiol: Separating the chemicals from the "weed," a pharmacodynamic discussion.Boggs DL, Peckham A, Boggs AA, Ranganathan M. Ment Health Clin. 2016 Nov; 2016 Nov 3. PMID: 29955482.
• MAHILA: a protocol for evaluating a nurse-delivered mHealth intervention for women with HIV and psychosocial risk factors in India.Reynolds NR, Satyanarayana V, Duggal M, Varghese M, Liberti L, Singh P, Ranganathan M, Jeon S, Chandra PS. BMC Health Serv Res. 2016 Aug 4; 2016 Aug 4. PMID: 27491288.
• Reduced Brain Cannabinoid Receptor Availability in Schizophrenia.Ranganathan M, Cortes-Briones J, Radhakrishnan R, Thurnauer H, Planeta B, Skosnik P, Gao H, Labaree D, Neumeister A, Pittman B, Surti T, Huang Y, Carson RE, D'Souza DC. Biol Psychiatry. 2016 Jun 15; 2015 Aug 29. PMID: 26432420.
• Feasibility and success of cell-phone assisted remote observation of medication adherence (CAROMA) in clinical trials.DeWorsop D, Creatura G, Bluez G, Thurnauer H, Forselius-Bielen K, Ranganathan M, Deaso E, Bhat JA, D'Souza DC. Drug Alcohol Depend. 2016 Jun 1; 2016 Mar 25. PMID: 27068252.
• Human Laboratory Studies on Cannabinoids and Psychosis.Sherif M, Radhakrishnan R, D'Souza DC, Ranganathan M. Biol Psychiatry. 2016 Apr 1; 2016 Feb 2. PMID: 26970363.
• Marijuana and Madness: Associations Between Cannabinoids and Psychosis.Ranganathan M, Skosnik PD, D'Souza DC. Biol Psychiatry. 2016 Apr 1. PMID: 26970361.
• Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050.Naganawa M, Dickinson GL, Zheng MQ, Henry S, Vandenhende F, Witcher J, Bell R, Nabulsi N, Lin SF, Ropchan J, Neumeister A, Ranganathan M, Tauscher J, Huang Y, Carson RE. J Pharmacol Exp Ther. 2016 Feb; 2015 Dec 1. PMID: 26628406.
• Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis.D'Souza DC, Cortes-Briones JA, Ranganathan M, Thurnauer H, Creatura G, Surti T, Planeta B, Neumeister A, Pittman B, Normandin MD, Kapinos M, Ropchan J, Huang Y, Carson RE, Skosnik PD. Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Jan; 2015 Oct 22. PMID: 29560896.
• Cannabinoids and Psychosis.D'Souza DC, Radhakrishnan R, Sherif M, Cortes-Briones J, Cahill J, Gupta S, Skosnik PD, Ranganathan M. Curr Pharm Des. 2016. PMID: 27568729.
• Rapid Changes in CB1 Receptor Availability in Cannabis Dependent Males after Abstinence from Cannabis.D'Souza DC, Cortes-Briones JA, Ranganathan M, Thurnauer H, Creatura G, Surti T, Planeta B, Neumeister A, Pittman B, Normandin M, Kapinos M, Ropchan J, Huang Y, Carson RE, Skosnik PD. Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Jan 1. PMID: 26858993.
• The early identification of psychosis: can lessons be learnt from cardiac stress testing?Gupta S, Ranganathan M, D'Souza DC. Psychopharmacology (Berl). 2016 Jan; 2015 Nov 14. PMID: 26566609.
• The psychosis-like effects of Δ(9)-tetrahydrocannabinol are associated with increased cortical noise in healthy humans.Cortes-Briones JA, Cahill JD, Skosnik PD, Mathalon DH, Williams A, Sewell RA, Roach BJ, Ford JM, Ranganathan M, D'Souza DC. Biol Psychiatry. 2015 Dec 1; 2015 Mar 30. PMID: 25913109.
• Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine.Ahn KH, Sewell A, Elander J, Pittman B, Ranganathan M, Gunduz-Bruce H, Krystal J, D'Souza DC. Neuropsychopharmacology. 2015 Nov; 2015 May 8. PMID: 25953357.
• Δ9-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans.Cortes-Briones J, Skosnik PD, Mathalon D, Cahill J, Pittman B, Williams A, Sewell RA, Ranganathan M, Roach B, Ford J, D'Souza DC. Neuropsychopharmacology. 2015 Aug; 2015 Apr 24. PMID: 25709097.
• GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THC.Radhakrishnan R, Skosnik PD, Cortes-Briones J, Sewell RA, Carbuto M, Schnakenberg A, Cahill J, Bois F, Gunduz-Bruce H, Pittman B, Ranganathan M, D'Souza DC. Neuropsychopharmacology. 2015 Jul; 2015 Mar 2. PMID: 25728472.
• Medical Marijuana: Is the Cart Before the Horse?D'Souza DC, Ranganathan M. JAMA. 2015 Jun 23-30. PMID: 26103026.
• Testing differences in the activity of event-related potential sources: important implications for clinical researchers.Cortes-Briones JA, Cahill JD, Ranganathan M, Sewell RA, D'Souza DC, Skosnik PD. Clin Neurophysiol. 2015 Jan; 2014 Apr 30. PMID: 24840905.
• In vivo evidence for β2 nicotinic acetylcholine receptor subunit upregulation in smokers as compared with nonsmokers with schizophrenia.Esterlis I, Ranganathan M, Bois F, Pittman B, Picciotto MR, Shearer L, Anticevic A, Carlson J, Niciu MJ, Cosgrove KP, D'Souza DC. Biol Psychiatry. 2014 Sep 15; 2013 Nov 13. PMID: 24360979.
• Effects of Δ9-tetrahydrocannabinol in individuals with a familial vulnerability to alcoholism.Ranganathan M, Sewell RA, Carbuto M, Elander J, Schnakenberg A, Radhakrishnan R, Pittman B, D'Souza DC. Psychopharmacology (Berl). 2014 Jun; 2014 Jan 15. PMID: 24424782.
• The endocannabinoid system and schizophrenia: links to the underlying pathophysiology and to novel treatment approaches.Gupta S, Cahill JD, Ranganathan M, Correll CU. J Clin Psychiatry. 2014 Mar. PMID: 24717381.
• Effects of nicotine on the neurophysiological and behavioral effects of ketamine in humans.Mathalon DH, Ahn KH, Perry EB Jr, Cho HS, Roach BJ, Blais RK, Bhakta S, Ranganathan M, Ford JM, D'Souza DC. Front Psychiatry. 2014; 2014 Jan 24. PMID: 24478731.
• Pilot study of intravenous nicotine effects on cognitive performance in schizophrenia.Boggs DL, Ranganathan M, Sewell RA, Madonick S, D'Souza DC. Schizophr Res. 2013 Oct; 2013 Aug 13. PMID: 23953216.
• Acute effects of THC on time perception in frequent and infrequent cannabis users.Sewell RA, Schnakenberg A, Elander J, Radhakrishnan R, Williams A, Skosnik PD, Pittman B, Ranganathan M, D'Souza DC. Psychopharmacology (Berl). 2013 Mar; 2012 Nov 24. PMID: 23179965.
• Treatment of hyperprolactinemia and gynecomastia with adjunctive aripiprazole in 2 men receiving long-acting injectable antipsychotics.Boggs DL, Ranganathan M, Boggs AA, Bihday CM, Peluse BE, D'Souza DC. Prim Care Companion CNS Disord. 2013. PMID: 24392257.
• Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans.Ranganathan M, Schnakenberg A, Skosnik PD, Cohen BM, Pittman B, Sewell RA, D'Souza DC. Biol Psychiatry. 2012 Nov 15; 2012 Jul 18. PMID: 22817868.
• Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia.D'Souza DC, Ahn K, Bhakta S, Elander J, Singh N, Nadim H, Jatlow P, Suckow RF, Pittman B, Ranganathan M. Biol Psychiatry. 2012 Nov 1; 2012 Jun 19. PMID: 22717030.
• Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans.Ranganathan M, Carbuto M, Braley G, Elander J, Perry E, Pittman B, Radhakrishnan R, Sewell RA, D'Souza DC. Int J Neuropsychopharmacol. 2012 Oct; 2012 Jan 16. PMID: 22243563.
• Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ⁹-THC in humans.D'Souza DC, Fridberg DJ, Skosnik PD, Williams A, Roach B, Singh N, Carbuto M, Elander J, Schnakenberg A, Pittman B, Sewell RA, Ranganathan M, Mathalon D. Neuropsychopharmacology. 2012 Jun; 2012 Feb 15. PMID: 22334121.
• Cannabinoids, working memory, and schizophrenia.Skosnik PD, Ranganathan M, D'Souza DC. Biol Psychiatry. 2012 Apr 15. PMID: 22449262.
• Lower ß2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia.D'Souza DC, Esterlis I, Carbuto M, Krasenics M, Seibyl J, Bois F, Pittman B, Ranganathan M, Cosgrove K, Staley J. Am J Psychiatry. 2012 Mar. PMID: 22193533.
• Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence.D'Souza DC, Singh N, Elander J, Carbuto M, Pittman B, Udo de Haes J, Sjogren M, Peeters P, Ranganathan M, Schipper J. Neuropsychopharmacology. 2012 Mar; 2011 Nov 23. PMID: 22113087.
• The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories.Carbuto M, Sewell RA, Williams A, Forselius-Bielen K, Braley G, Elander J, Pittman B, Schnakenberg A, Bhakta S, Perry E, Ranganathan M, D'Souza DC. Psychopharmacology (Berl). 2012 Feb; 2011 Aug 16. PMID: 21845389.
• [Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia].Sewell RA, Skosnik PD, Garcia-Sosa I, Ranganathan M, D'Souza DC. Braz J Psychiatry. 2010 May. PMID: 20512267.
• Cannabis and psychosis/schizophrenia: human studies.D'Souza DC, Sewell RA, Ranganathan M. Eur Arch Psychiatry Clin Neurosci. 2009 Oct; 2009 Jul 16. PMID: 19609589.
• The effects of cannabinoids on serum cortisol and prolactin in humans.Ranganathan M, Braley G, Pittman B, Cooper T, Perry E, Krystal J, D'Souza DC. Psychopharmacology (Berl). 2009 May; 2008 Dec 16. PMID: 19083209.
• Cannabinoids and psychosis.Sewell RA, Ranganathan M, D'Souza DC. Int Rev Psychiatry. 2009 Apr. PMID: 19367509.
• Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis.D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, Perry E, Krystal J. Neuropsychopharmacology. 2008 Sep; 2008 Jan 9. PMID: 18185500.
• Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans.D'Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B, Ranganathan M, Bhakta S, Zimolo Z, Cooper T, Perry E. Psychopharmacology (Berl). 2008 Jul; 2008 Jan 29. PMID: 18228005.
• The acute effects of cannabinoids on memory in humans: a review.Ranganathan M, D'Souza DC. Psychopharmacology (Berl). 2006 Nov; 2006 Sep 26. PMID: 17019571.
• Evoked gamma band response in male adolescent subjects at high risk for alcoholism during a visual oddball task.Padmanabhapillai A, Tang Y, Ranganathan M, Rangaswamy M, Jones KA, Chorlian DB, Kamarajan C, Stimus A, Kuperman S, Rohrbaugh J, O'Connor SJ, Bauer LO, Schuckit MA, Begleiter H, Porjesz B. Int J Psychophysiol. 2006 Nov; 2006 Aug 2. PMID: 16887227.
• Suppression of early evoked gamma band response in male alcoholics during a visual oddball task.Padmanabhapillai A, Porjesz B, Ranganathan M, Jones KA, Chorlian DB, Tang Y, Kamarajan C, Rangaswamy M, Stimus A, Begleiter H. Int J Psychophysiol. 2006 Apr; 2005 Jul 12. PMID: 16019097.